A few months after the American Chemical Society won its lawsuit against the pirate site, the game of virtual whack-a-mole continues.
The Scientist is bringing together a panel of experts to share their experience with biomarker discovery and validation for Parkinson's Disease.
August 2, 2017|
In the absence of new diagnostic tests for Parkinson’s disease (PD), the diagnosis has long been one of exclusion, ruling out other causes of tremor, bradykinesia, and rigidity. With the dawn of biomarker-based molecular diagnostics, a new race has begun to identify molecular signatures of disease pathology in noninvasively derived tissue samples, including blood, urine, and saliva, as well as radiographic or magnetic scans. Scientists have begun to sort through the molecular traces associated with PD patients to find telltale signs of disease onset and progression. The Scientist is bringing together a panel of experts to share their experience with biomarker discovery and validation, as well as their predictions for this as-yet-untapped market. Attendees will have the opportunity to interact with the experts, ask questions, and seek advice on topics that are related to their research.
Topics to be covered:
Brit Mollenhauer, MD
Assistant Professor, Department of Neuropathology
University Medical Center, Goettingen, Germany
Paracelsus-Elena-Klinik, Kassel, Germany
Hugo Vanderstichele, PhD
Cofounder and Chief Integration Officer, ADx Neurosciences
Founder, Biomarkable bvba